Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: Health Care Equipment
- Exchange: NASDAQ
- Symbol: HOLX
- CUSIP: 43644010
- Previous Close: $40.09
- 50 Day Moving Average: $39.894
- 200 Day Moving Average: $38.848
- 52-Week Range: $32.64 - $41.24
- Trailing P/E Ratio: 34.397
- Foreward P/E Ratio: 19.09
- P/E Growth: 2.390
- Market Cap: $11.24B
- Outstanding Shares: 279,296,000
- Beta: 1.1
- Net Margins: 11.57%
- Return on Equity: 27.17%
- Return on Assets: 7.86%
Companies Related to Hologic:
- Debt-to-Equity Ratio: 1.17%
- Current Ratio: 1.81%
- Quick Ratio: 1.61%
What is Hologic's stock symbol?
Hologic trades on the NASDAQ under the ticker symbol "HOLX."
Where is Hologic's stock going? Where will Hologic's stock price be in 2017?
14 equities research analysts have issued 12-month target prices for Hologic's shares. Their predictions range from $39.00 to $48.00. On average, they anticipate Hologic's stock price to reach $44.43 in the next twelve months.
When will Hologic announce their earnings?
Hologic is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.
What are analysts saying about Hologic stock?
Here are some recent quotes from research analysts about Hologic stock:
- Needham & Company LLC analysts commented, "HOLX is acquiring Cynosure (CYNO) for $1.44B with an all-cash tender offer. CYNO is a leading aesthetics company that competes in a $2B market growing in the double-digits with a range of products used for hair removal, body contouring, skin revitalization, and other cosmetic procedures. HOLX expects CYNO to increase its revenue growth and add $0.13-0.15 to its FY18E EPS. HOLX has now effectively swapped a business with declining sales and margins (blood screening) for one with double-digit growth and improving margins (CYNO). With the blood screening EPS "hole" now partially filled and HOLX facing increasingly easy comps over the next three quarters, we upgrade to Buy." (2/15/2017)
According to Zacks Investment Research, "Hologic delivered solid first quarter 2017 with both earnings and revenues ahead of the Zacks Consensus Estimate. We note that, the share price of Hologic, which outpaced the Zacks categorized Medical Instruments industry over the past three months, continues to trend higher banking on a solid quarterly performance. Segment-wise, barring skeletal Health, Hologic witnessed positive growth across all its business segments. However, a dismal guidance for the rest of fiscal 2017 concerns us. The blood screening divestiture and a stronger U.S. dollar are expected to mar the company's growth momentum in the upcoming period. On an impressive note, the loss making blood screening divestment should increase the company’s financial flexibility. Strong cash balance position also encourages us. Moreover, despite higher expenses, Hologic observed margin expansion on strong domestic sales growth, favorable product mix, and operational improvement." (2/3/2017)
Barclays PLC analysts commented, "stronger for longer" versus its previous expectations.The brokerage, who also upped the price target by $2 to $44, believes the breast health business will be able to sustain its L-MSD growth with a longer 3D mammography tail, service growth from 3D conversions, and new product launches such as Affirm."Our FDA mammography market model improves our conviction in the durability of placements and Hologic share gains," analyst Jack Meehan wrote in a note.In addition, the Meehan said the company's Panther system strengthened its leadership position at the high-end of MDx workflows and can drive L-MSD growth for the entire diagnostics business alone.Related Link: New 5-Year Contraceptive Coming To U.S. Adds To Long-Acting, Reversible Contraceptives List"The launch of the Fusion PCR sidecar in 2017/2018 will add additional flexibility to the instrument, which could lead to higher consumable pull-through, as the company expands its US menu beyond sexual health into virology," Meehan highlighted. Importantly, the analyst feels that Panther is "PAMA-proof" for upcoming Dx reimbursement changes, and could be an aggregator of share in a consolidating lab market. Further, the analyst expects at least HSD growth for the GYN Surgical unit from MyoSure strength."We believe that at current levels shares offer an attractive entry point, flat YTD versus the S&P 500 up 6 percent and our coverage universe up 15 percent," (9/23/2016)
Who owns Hologic stock?
Hologic's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.49%), Alyeska Investment Group L.P. (0.67%), Dimensional Fund Advisors LP (0.65%), Investec Asset Management LTD (0.61%), Franklin Resources Inc. (0.55%) and Renaissance Technologies LLC (0.52%). Company insiders that own Hologic stock include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming, Peter J Valenti III and Wayne Wilson.
Who sold Hologic stock? Who is selling Hologic stock?
Hologic's stock was sold by a variety of institutional investors in the last quarter, including Prudential PLC, Tudor Investment Corp Et Al, AQR Capital Management LLC, Dimensional Fund Advisors LP, Guggenheim Capital LLC, Brown Advisory Inc., Oxford Asset Management and Ardevora Asset Management LLP. Company insiders that have sold Hologic stock in the last year include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming and Peter J Valenti III.
Who bought Hologic stock? Who is buying Hologic stock?
Hologic's stock was bought by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Investec Asset Management LTD, State Street Corp, Renaissance Technologies LLC, Asset Management One Co. Ltd., Marshall Wace LLP, Clough Capital Partners L P and Russell Investments Group Ltd..
How do I buy Hologic stock?
Shares of Hologic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Hologic stock cost?
One share of Hologic stock can currently be purchased for approximately $40.09.